**IN THE CLAIMS:**

1. (Original) Benzimidazole derivatives of formula I



I

wherein

$R^6$, $R^7$ are independently from one another H, A or $SO_2A$,

A is independently selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and alkoxyalkyl,

$Ar^2$ is selected independently from one another from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two heteroatoms, independently selected from N, O and S,

$R^8$, $R^9$ and $R^{10}$ are independently selected from a group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, $CH_2Hal$, $CH(Hal)_2$, $C(Hal)_3$, $NO_2$, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$,

$(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, CH=N-OA, $CH_2CH$=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-$R^{11}$, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$, $C(R^{13})HCOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, $CH=CHCOOR^{11}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{11})COOR^{12}$, $(CH_2)_nN(CONH_2)COOR^{11}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$, $(CH_2)_nN(CH_2CONH_2)COOR^{11}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{11}$, $(CH_2)_nCHR^{13}COOR^{11}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$, wherein

$R^{11}$, $R^{12}$ are independently selected from a group consisting of H, A, $(CH_2)_mAr^3$ and $(CH_2)_mHet$, or in $NR^{11}R^{12}$,

$R^{11}$ and $R^{12}$ form, together with the N-atom they are bound to, a 5-, 6- or 7-membered heterocyclus which optionally contains 1 or 2 additional hetero atoms, selected from N, O an S,

$R^{13}$, $R^{14}$ are independently selected from a group consisting of H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_mHet$,

$Ar^3$, $Ar^4$ are independently from one another aromatic hydrocarbon residues comprising 5 to 12 and preferably 5 to 10 carbon atoms which are optionally substituted by one or more substituents, selected from a group consisting of A, Hal, $NO_2$, CN, $OR^{15}$, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, $COR^{15}$, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one ore more substituents, selected from a group consisting of A, Hal, $NO_2$, CN, $OR^{15}$, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, $COR^{15}$, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$, .

$R^{15}$, $R^{16}$ are independently selected from a group consisting of H, A, and $(CH_2)_mAr^6$, wherein

$Ar^6$ is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from a group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, $NH_2$ and $CF_3$,

k, m and n are independently of one another 0, 1, 2, 3, 4, or 5,

X represents a bond or is $(CR^{11}R^{12})_h$, or $(CHR^{11})_h$-Q-$(CHR^{12})_i$, wherein

Q is selected from a group consisting of O, S, N-R15, $(CHal_2)_j$, $(O\text{-}CHR^{18})_j$, $(CHR^{18}\text{-}O)_j$, $CR^{18}=CR^{19}$, $(O\text{-}CHR^{18}CHR^{19})_j$, $(CHR^{18}CHR^{19}\text{-}O)_j$, C=O, C=S, $C=NR^{15}$, $CH(OR^{15})$, $C(OR^{15})(OR^{20})$, C(=O)O, OC(=O), OC(=O)O, $C(=O)N(R^{15})$, $N(R^{15})C(=O)$, $OC(=O)N(R^{15})$, $N(R^{15})C(=O)O$, CH=N-O, $CH=N\text{-}NR^{15}$, S=O, $SO_2$, $SO_2NR^{15}$ and $NR^{15}SO_2$, wherein

$R^{18}$, $R^{19}$, $R^{20}$ are independently selected from the meanings given for $R^8$, $R^9$ and $R^{10}$, preferably independently selected from the group consiting of H, A, Hal, $CH_2Hal$, $CH(Hal)_2$, $C(Hal)_3$, $NO_2$, $(CH_2)_nCN$, $(CH_2)_nOR^{11}$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOOR^{13}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, $(CH_2)_nNHOA$ and $(CH_2)_nNR^{11}COOR^{13}$,

h, i are independently from each other 0, 1, 2, 3, 4, 5, or 6, and

j is 1, 2, 3, 4, 5, or 6,

Y is selected from O, S, $NR^{21}$, $C(R^{22})\text{-}NO_2$, $C(R^{22})$-CN and $C(CN)_2$, wherein

$R^{21}$ is independently selected from the meanings given for $R^{13}$, $R^{14}$ and

$R^{22}$ is independently selected from the meanings given for $R^{11}$, $R^{12}$,

p, r are independently from one another 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4, preferably 0, 1 or 2,

u is 0, 1, 2 or 3, preferably 0, 1 or 2,

and

Hal is independently selected from a group consisting of F, Cl, Br and I;

and the physiologically acceptable derivatives, salts and solvates thereof.

2. (Original) Benzimidazole derivative according to claim 1, wherein

$Ar^2$ is selected from aromatic hydrocarbons containing 6 to 10 and especially 6 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 8 and especially 4 to 6 carbon atoms and one or two heteroatoms, independently selected from N, O and S and especially selected from N and O,

$R^8$, $R^9$ and $R^{10}$ are independently selected from a group consisting of H, A, cycloalkyl 3 to 7 carbon atoms, Hal,

$CH_2Hal$, $CH(Hal)_2$, $C(Hal)_3$, $NO_2$, $(CH_2)_nCN$, $(CH_2)_nOR^{11}$, $(CH_2)nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOOR^{13}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, $(CH_2)_nNHOA$, $(CH_2)_nNR^{11}COOR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^8$, $(CH_2)_nN(R^{11})$, $C(R^{13})HCOR^8$, $(CH_2)_nN(COOR^{13})COOR^{14}$, $(CH_2)_nN(CONH_2)COOR^{13}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{13})COOR^{14}$, $(CH_2)_nN(CH_2CONH_2)COOR^{13}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{14}$, $(CH_2)_nCHR^{13}COOR^{14}$ and $(CH_2)_nCHR^{13}CH_2OR^{14}$,

X represents a bond or is $(CR^{11}R^{12})_h$, or $(CHR^{11})_h$-Q-$(CHR^{12})_i$, wherein

Q is selected from a group consisting of O, S, N-$R^{15}$, $(CHal_2)_j$, (O-$CHR^{18})_j$, ($CHR^{18}$-O)$_j$, $CR^{18}$=$CR^{19}$, (O-$CHR^{18}CHR^{19})_j$, ($CHR^{18}CHR^{19}$-O)$_j$, C=O, C=$NR^{15}$, $CH(OR^{15})$, $C(OR^{15})(OR^{20})$, $C(=O)N(R^{15})$, $N(R^{15})C(=O)$, CH=N-$NR^{15}$, S=O, $SO_2$, $SO_2NR^{15}$ and $NR^{15}SO_2$, wherein

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6, preferably 0, 1, 2 or 3 and

j is 1, 2, 3, 4, 5 or 6, preferably 1, 2, 3 or 4,

p is 1, 2, 3 or 4, preferably 1, 2 or 3, and

r is 0, 1, 2, or 3, preferably 0, 1 or 2;

and the physiologically acceptable derivatives, salts and solvates thereof.

3. (Currently amended) Benzimidazole derivative according to claim 1 ~~or 2~~, selected from the compounds of the formulae Ia, Ib, Ic and Id,



Ia



Ib



Ic



Id

wherein

$R^7$, $R^8$, p, X, Y, $R^9$ and q are as defined in claims 1 ~~or 2~~, and $R^{10}$ is H or as defined in claims 1 ~~or 2~~;

and the physiologically acceptable derivatives, salts and solvates thereof.

4. (Original) Benzimidazole derivative according to claim 3, additionally comprising one or two substituents selected from the group consisting of $O(CH_2)_nNR^{11}R^{12}$, $NR^{11}(CH_2)_nNR^{11}R^{12}$, $O(CH_2)_nOR^{12}$ and $NR^{11}(CH_2)_nOR^{12}$,

wherein

$R^{11}$, $R^{12}$ are independently selected from a group consisting of H, A, $(CH_2)_mAr^3$ and $(CH_2)_mHet$, or in $NR^{11}R^{12}$,

$R^{11}$ and $R^{12}$ form, together with the N-atom they are bound to, a 5-, 6- or 7-membered heterocyclus which optionally contains 1 or 2 additional hetero atoms, selected from N, O an S, and

n is 1, 2, 3, 4, 5 or 6.

5. (Currently amended) Benzimidazole derivative according to ~~one of the~~ claim~~s~~ 1 ~~to 4~~, selected from the compounds (1) to (78) of table 1; and the physiologically acceptable derivatives, salts and solvates thereof.

6. (Currently amended) Benzimidazole derivative according to ~~one of the~~ claim~~s~~ 1 ~~to 5~~ as a medicament.

7. (Currently amended) Benzimidazole derivative according to ~~one of the~~ claim~~s~~ 1 ~~to 5~~ as a kinase inhibitor.

8. (Original) Benzimidazole derivative according to claim 7, characterized in that the kinases are selected from raf-kinases and VEGFR kinases.

9. (Currently amended) Pharmaceutical composition, characterized in that it contains one or more compounds according to ~~one of the~~ claim~~s~~ 1 ~~to 5~~.

10. (Currently amended) Pharmaceutical composition according to claim 9, characterised in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients ~~other than the compounds according to one of the claims 1 to 5~~.

11. (Currently amended) Process for the manufacture of a pharmaceutical composition, characterised in that one or more compounds according to ~~one of the~~ claim~~s~~ 1 ~~to 5~~ and one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compounds according to ~~one of the~~ claim~~s~~ 1 ~~to 5~~, is processed by mechanical means into a pharmaceutical composition that is suitable as dosageform for application and/or

administration to a patient.

12. (Currently amended) Use of a compound according to ~~one of the~~ claims 1 ~~to 5~~ as a pharmaceutical.

13. (Currently amended) Use of a compound according to ~~one of the~~ claims ~~1~~ ~~to 5~~ in the treatment and/or prophylaxis of disorders.

14. (Currently amended) Use of a compound according to ~~one of the~~ claims 1 ~~to 5~~ for producing a pharmaceutical composition for the treatment and/or prophylaxis of disorders.

15. (Currently amended) Use according to claim 13 ~~or 14~~, characterised in that the disorders are caused, mediated and/or propagated by kinases selected from raf-kinases and VEGFR kinases.

16. (Currently amended) Use according to claim 13, ~~14 or 15,~~ characterised in that the disorders are selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.

17. (Currently amended) Use according to claim 13, ~~14, 15 or 16,~~ characterised in that the disorder is cancer.

18. (Currently amended) Use according to claim 13, ~~14, 15 or 16,~~ characterised in that the disorder is noncancerous.

19. (Currently amended) Use according to claim ~~13, 14, 15, 16 or~~ 18, characterised in that the noncancerous disorders are selected from the group consisting of infection, psoriasis, arthritis, inflammation, endometriosis, scarring, begnin prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.

20. (Currently amended) Use according to ~~one of the~~ claims ~~13 to~~ 17, characterised in that the disorders are selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.

21. (Currently amended) Use according to ~~one of the~~ claims 13 ~~to 16 and 18~~, characterised in that the disorders are selected from the group consisting of arthritis, restenosis; fibrotic disorders; mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation and neurodegenerative diseases.

22. (Currently amended) Use according to ~~one of the~~ claims ~~13~~ 13 ~~to 18~~, characterised in that the disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease and angiogenesis disorders.

23. (Currently amended) Use of a compound according to ~~one of the~~ claims 1 ~~to 5~~ as a kinase inhibitor.

24. (Original) Use according to claim 23, characterised in that the kinase is one or more raf-kinases, selected from the group consisting of A-Raf, B-Raf and Raf-1.

25. (Currently amended) Method for the treatment and/or prophylaxis of disorders, characterised in that one or more compounds according to ~~one of the~~ claims 1 ~~to 5~~ is administered to a patient in need of such a treatment.

26. (Currently amended) Method according to claim 25, characterised in that the ~~one or more~~ compounds ~~according to one of the claims claim 1 to 5~~ are administered as a pharmaceutical composition ~~according to claim 9 or 10~~.

27. (Currently amended) Method for the treatment and/or prophylaxis of disorders according to claim 25, characterised in that the disorders are ~~as defined in one of the claims 15 to 22~~ caused, mediated and/or propagated by kinases selected from raf-kinases and VEGFR kinases.

28. (Original) Method for the treatment according to claim 27, characterised in that the disorders is cancerous cell growth mediated by one or more kinases.

29. (Original) Method for producing compounds of formula I, characterised in that

a) a compound of formula II



II

wherein

$L^1$ is H or a metal ion, and $R^6$, $R^7$, $R^8$ and p are as defined in claim 1,

is reacted

b) with a compound of formula III,



III

wherein

$L^2$ is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and Y, $R^9$, q, X, $Ar^2$, $R^{10}$ and r are as defined in claim 1,

and optionally

c) isolating and/or treating the compound of formula I obtained by said reaction withan acid, to obtain the salt thereof.

30. (Original) Compound of formula II,



II

wherein

$L^1$ is H or a metal ion, and $R^6$, $R^7$, $R^8$ and p are as defined in claim 1.

31. (Original) Compound of formula III,



III

wherein

$L^2$ is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and Y, $R^9$, q, X, $Ar^2$, $R^{10}$ and r are as defined in claim 1.